Five-year survival rate of 81.4% for two-year patients treated with NSCLC on the first line of Keytruda in Meshadon

Merck and Co recently presented five-year survival data for the first-line treatment of non-small cell lung cancer (NSCLC) in the key Phase III NOTE-024 trial of the anti-PD-1 therapy Keytruda (Corida, generic name: pembrolizumab, Pabli pearl monoantigen) at the 2020 Virtual Conference of the European Society of Medical Oncology (ESMO). It is worth mentioning that the results from the KEYNOTE-024 study represent the longest follow-up and first 5-year survival data of immunotherapy in the NSCLC first-line treatment random phase 3 study.The results showed that in patients with metastasis NSCLC with tumor expression PD-L1 (TPS≥50%) and no EGFR or ALC genomic tumor distortion, Keytruda first-line therapy showed long-lasting long-term survival benefits and long-lasting response compared to chemotherapy. Although 66% of the patients in the chemotherapy group switched from chemotherapy to follow-up anti-PD-1/PD-L1 therapy, the total survival (OS) rate of the Keytruda group was twice (31.9% vs 16.3%) after 5 years. Keytruda reduced the risk of death by 38% (HR-0.62; 95% CI: 0.48-0.81) compared to chemotherapy, with a significantly longer total lifetime (medium OS: 26.3 months vs. 13.4 months). In addition, Keytruda reduced the risk of disease progress or death by 50% (HR-0.50; 95% CI: 0.39-0.65) and increased progressity-free lifetime (medium PFS: 7.7 months vs 5.5 months), improved objective mitigation rate (ORR: 46.1% vs 31.1%), and 5 times the duration of mitigation (29.1 months vs 6.3 months).In particular, 81.4 per cent of patients who completed two years of treatment with Keytruda (n-39/154) survived five years and nearly half (46 per cent) did not receive treatment. These data suggest that patients treated with Keytruda for 2 years can benefit from long-term OS. For patients who completed 2 years of Keytruda treatment, the ORR was 82%. In addition, 12 patients received a second course of treatment.No new security signals for Keytruda were found during the long follow-up. Of all the patients treated, 31.2% of those treated with Keytruda and 53.3% of those treated with chemotherapy had treatment-related adverse events (TRAEs) of level 3-5. The rate of TRAE at level 3-5 was 15.4% in patients treated with Keytruda for 2 years. (Bio Valley)